Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
205 Leser
Artikel bewerten:
(1)

Regenerative Medical Technology Group: Regenerative Medical Technologies Group Increases Q1 2025 Sales By 67% Over Q1 2024 and Achieves Operating Profit for the Quarter of $134,000

Regenerative Medical Technologies Group, Inc. $RMTG, a regenerative medicine company, is pleased to announce that sales for its first quarter of 2025 surpassed $1.35M and achieved operational profits of $134,000 for the quarter.

LAS VEGAS, NV / ACCESS Newswire / May 21, 2025 / Regenerative Medical Technologies Group, Inc. (the "Company" or "RMTG"), a regenerative medicine company is pleased to announce that sales for its first quarter of 2025 surpassed $1.35M, a 67% increase over sales for the same quarter in 2024. The Company also achieved operational profits of $134,000 for the quarter.

As sales continue to increase and the overall industry continues to gain momentum, the Company has introduced a new revenue stream. The Company has commenced selling Turnkey exclusive memberships, where new members pay a fee upfront in exchange for turnkey assistance in setting up a regenerative medical clinic in their area along with continuous training and support. The members are bound to purchase all supplies exclusively from RMTG. RMTG expects to onboard one new member per quarter for now and expects to increase this rate of onboarding significantly as of next year.

"We are extremely pleased with this quarter's performance and continuing our significant trend of positive operating income. We expect to see continued revenue growth in our four lines of business and sustained increases in operating income," said David Christensen CEO/President of the Company.

The Company expects to issue official guidance on revenues for the remainder of this year and for the next 2 years in a subsequent press release in the near future.

This press release should be read in conjunction with all of the company's filings on www.sec.gov

About Regenerative Medical Technologies Group, Inc.

Regenerative Medical Technologies Group, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun. The Company distributes stem cells and other regenerative based cell lines and equipment internationally and also specializes in education and training physicians in the area of regenerative medicine.

For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com

Forward Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Regenerative Medical Technologies Group, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Regenerative Medical Technologies Group, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

For further information, please contact: investor.relations@regenmedtechgroup.com

SOURCE: Regenerative Medical Technology Group



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/regenerative-medical-technologies-group-increases-q1-2025-sales-by-67-1030131

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.